Daniel Przybysz

Dr. Daniel Przybysz (born March 25, 1988) is a Brazilian Radiation-Oncologist. His practice is mainly focused on lung cancer treatment and high technology approaches toward better patient care

Przybysz has a medical degree from the Federal University of Parana, Brazil jointly with Harvard Medical School. He graduated in 2013 with high-honors after doing his internships in Oncology-related rotations.

After spending some time at the Massachusetts General Hospital in Boston and at the University of Texas MD Anderson Cancer Center, Przybysz began a Radiation-Oncology program at the Brazilian National Cancer Institute. He graduated residency and was invited to start a position as Visitor Researcher in Radiation-Oncology at the Washington University School of Medicine.

Przybysz also works as an Oncology Reviewer for UpToDate and as an author, editor and reviewer for lung-related articles at the International Journal of Radiation Oncology, Biology and Physics, contributing on high-level reviews for medical content.

Publications Przybysz's interest in clinical cancer research and outcomes has culminated in several publications, some of listed below:

Magnetic Resonance Image-Guided Radiation Therapy (MR-IGRT) for the Treatment of Prostate Cancer: Initial Patient Selection and Clinical Experience - Journal of Urology 2017 Lung SBRT using MRI-guided radiation therapy: possible GTV changes and benefits of adaptive therapy In Silico Trial of MR-Guided Mid-Treatment Adaptive Planning for Hypofractionated Stereotactic Radiotherapy in Centrally Located Thoracic Tumors - IJROBP 2016 Lung SBRT using MRI-guided radiation therapy: possible GTV changes and benefits of adaptive therapy - SBRT 2016

A comparison between VMAT, IMRT and GAP techniques on the Medulloblastoma approach: different technologies aiming better patient care - Radiology 2015 Potential benefits of Neoadjuvant Radiation Therapy On Overall Survival in Advanced Breast Cancer Patients - Radiology 2016

Nevertheless, Przybysz is now developing projects using high-technology treatment planning towards better patient care. At present, he is engaged in several studies regarding lung cancer, CNS malignancies and prostate cancer.

He has been recognized and awarded as a Leading Physician of The World by the International Association of Healthcare Providers in 2017.